Immunoproteomics

Mass Spectrometry-based Methods to Study the Targets of the Immune Response*

A. W. Purcell{ddagger},§ and J. J. Gorman

From the {ddagger} Department of Microbiology and Immunology and ImmunoID, The University of Melbourne, Victoria 3010, Australia; and Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland 4072, Australia


    ABSTRACT
 TOP
 ABSTRACT
 ROLE OF PROTEOMICS IN...
 REFERENCES
 
The mammalian immune system has evolved to display fragments of protein antigens derived from microbial pathogens to immune effector cells. These fragments are typically peptides liberated from the intact antigens through distinct proteolytic mechanisms that are subsequently transported to the cell surface bound to chaperone-like receptors known as major histocompatibility complex (MHC) molecules. These complexes are then scrutinized by effector T cells that express clonally distributed T cell receptors with specificity for specific MHC-peptide complexes. In normal uninfected cells, this process of antigen processing and presentation occurs continuously, with the resultant array of self-antigen-derived peptides displayed on the surface of these cells. Changes in this peptide landscape of cells act to alert immune effector cells to changes in the intracellular environment that may be associated with infection, malignant transformation, or other abnormal cellular processes, resulting in a cascade of events that result in their elimination. Because peptides play such a crucial role in informing the immune system of infection with viral or microbial pathogens and the transformation of cells in malignancy, the tools of proteomics, in particular mass spectrometry, are ideally suited to study these immune responses at a molecular level. Here we review recent advances in the studies of immune responses that have utilized mass spectrometry and associated technologies, with specific examples from collaboration between our laboratories.


The mammalian immune system has evolved to act as a sentinel for changes in the body that may be associated with pathological processes. To do this, it requires a mechanism whereby normal healthy cells are distinguished from infected or malignant cells. Early studies characterized this as the self-nonself paradigm, and distinction between these two states was broadly defined as the function of the immune system. This model was challenged more recently where it was suggested that the immune system functioned to recognize "danger signals" (1, 2), which, for example, may be in the form of bacterial cell wall components, viral nucleic acids, or uncontrolled malignant growth. Thus in most cases, immune responses are initiated following activation of immune effector cells through the presence of "danger signals" and specific recognition of foreign peptides derived from pathogen antigens or neoantigens found in cancerous cells. The response toward pathogens in a naïve individual involves an initial nonspecific response facilitated by innate immune mechanisms followed shortly afterward via the adaptive immune response. Two arms of adaptive immunity, the antibody or humoral immune response and the cellular immune response, act in concert to combat infection and malignancy in an antigen-specific manner. Fig. 1 depicts the different arms of the adaptive immune response and highlights both the cell types and MHC molecules involved in the recognition process. The first arm of the cellular immune response includes T helper lymphocytes that control antibody-secreting cells and the generation of cytotoxic T lymphocytes, the second major effector arm of the adaptive immune system. Antigen-presenting cells (APC)1 sample both endogenous and exogenous proteins and display the proteolytically excised peptide antigens generated through antigen processing to the effector cells and molecules of the immune system, in a process that is analogous to a complex cellular proteomics experiment. However, the recognition of peptide antigens by T lymphocytes and by antibodies is exquisitely specific and sensitive, and in most cases the sensitivity of this functional recognition in vivo greatly exceeds that of modern proteomics procedures. Nevertheless, delineation of many of the molecular events involved in antigen processing has been facilitated by modern proteomics techniques. This review will describe some of the molecular events involved in antigen processing by the two arms of the cellular immune response, how proteomics has impacted on our current understanding of these processes and the potential for the latest technologies to enhance our knowledge.



View larger version (42K):
[in this window]
[in a new window]
 
FIG. 1. The interplay of APCs, helper T lymphocytes, B cells, and CD8+ T cells in the induction of humoral and cell-mediated immunity. The first step in the generation of an antibody response is the uptake of antigen by an APC. Complex antigens undergo proteolysis to form peptides, some of which are bound by MHC class II molecules and are then transported to the surface of the APC. Helper T cells that bear receptors capable of interacting with the peptide-class II complexes can then bind to the APC. Additional interactions occur through costimulatory molecules and their ligands expressed on APC and T cells, respectively. These recognition events result in the transmission of activation signals to the T cell. The activated T cell is now poised to respond to those B cells that display the same peptide-class II complexes on their surfaces, acquired as a result of internalization of the immunogen through specific surface immunoglobulin receptors (B cell receptor, BCR). It is this interaction between T cells and B cells that is termed "help" and results in triggering of the B cell to differentiate into a plasma cell capable of secreting antibody of the same specificity as that of the immunoglobulin receptor. The interaction of activated helper T cells with certain subsets of APC can license these APC to stimulate naïve CD8+ T cells. Presentation of appropriate peptide epitopes to a naïve CD8+ T cells by such an activated APC results in the generation of CD8+ cytotoxic T cells that are able to recognize and kill target cells that display a viral or tumor peptide in the context of MHC class I molecules. Cytokines are also produced by each cell type, which profoundly influences the type of immune response that is elicited.

 
Cytotoxic T Lymphocytes: The Assassins of the Immune System
The cytotoxic T cell response is implemented by lymphocytes expressing the CD8 coreceptor. This coreceptor facilitates recognition of major histocompatibility complex (MHC) class I molecules complexed to antigenic peptides that are expressed on the surface of all nucleated cells. It is through these cytotoxic T lymphocyte (CTL) responses that virally infected cells, tumor cells, and sometimes even normal healthy cells are destroyed, clearing the virus or eradicating tumor cells from the host. In the case of normal tissue destruction, the result is overt autoimmune disease such as that observed in the destruction of pancreatic ß cells in type 1 diabetes. The structure of class I MHC molecules is well defined and consists of a polymorphic heavy chain, a monomorphic light chain (ß2 microglobulin), and an antigenic peptide (Fig. 2A). The class I heavy chain has three extracellular domains ({alpha}1, {alpha}2 domains that together form the antigen-binding cleft, and the membrane-proximal {alpha}3 domain, which is linked to a transmembrane domain and a short cytoplasmic tail). The antigen-binding cleft is composed of an eight-stranded anti-parallel ß-pleated sheet floor bounded by helices from the {alpha}1 and {alpha}2 domains. This peptide-binding groove accommodates an antigenic peptide typically 8–11 amino acid residues in length. Heavy chain residues that line the binding groove are the focus for the majority of class I MHC polymorphisms, which in turn determine the antigen specificity of different allelic forms of MHC molecules via the formation of several conserved depressions or pockets (denoted A–F) that vary in composition and stereochemistry. The A and F pockets are located at either end of the cleft and contain conserved residues involved in hydrogen-bonding interactions with the N and C termini of the bound peptide, respectively. These interactions effectively close off each end of the cleft encapsulating the termini of the bound peptide. The A pocket is frequently shallow, while the stereochemistry of the F pocket varies significantly and contributes both to conserved interactions with the C termini as well as to the specificity of the last amino acid residue of the bound peptide ligand. The B, C, D, and E pockets contribute to the specificity of the central portion of the bound peptide. Our understanding of binding specificity and its relationship to MHC polymorphism has come both from structural studies of class I molecules that bind to different peptide antigens and from the biochemical analysis of peptides that are bound by different class I molecules. Typically biochemical analysis involves either Edman chemistry and/or mass spectrometry (324).



View larger version (37K):
[in this window]
[in a new window]
 
FIG. 2. MHC class I molecular structure and antigen-processing pathway. A, The three-dimensional structure of a class I molecule. The class I heterodimer acts as a platform to which peptide antigen binds (shown in the green space-filling model). The class I heavy chain (shown in blue ribbon form) has three domains. {alpha}1 and {alpha}2 form the peptide-binding groove; this groove is lined with the highest density of polymorphic residues that impact on ligand specificity of the MHC molecule. The {alpha}3 domain is the membrane-proximal domain and lies adjacent to the monomorphic ß2-microglobulin molecule (shown in red ribbon form). This figure was generated from the Protein Data Bank coordinates (accession number 1N2R) of HLA B*4403 bound to an endogenous peptide derived from HLA DP{alpha} chain (66, 187). B, Antigen processing in the MHC class I pathway. 1, Protein antigen is degraded in the cytoplasm through the actions of the proteasome a multi-subunit protease complex with several defined proteolytic activities, some of which are induced through proinflammatory cytokines. 2, Peptides generated by the proteasome and by other cytosolic proteases are transported into the lumen of the ER in an ATP-dependent manner through the actions of the TAP heterodimer. 3, Nascent class I heavy chain is targeted to the ER and stabilized by interacting with the chaperone calnexin. Once ß2-microglobulin associates with the class I heavy chain, calnexin is exchanged for another ER-resident chaperone, calreticulin. The association of the class I heterodimer with calreticulin is also associated with the recruitment of other members of the PLC, including tapasin and ERp57. ERp57 is a thiol oxidoreductase (188, 189) involved in assuring correct disulfide bonding of the class I heavy chain (190192), and tapasin is a 48-kDa glycoprotein that bridges peptide-receptive class I heterodimers to the TAP heterodimer (193195). 4, Once a peptide of sufficient affinity binds to the class I heterodimer, this complex dissociates from the PLC and is transported to the cell surface, where it may be recognized by CD8+ T cells (5).

 
Protein antigens destined for the class I-processing pathway are degraded to oligopeptides predominantly in the cytoplasm through the action of a multi-catalytic protease structure known as the proteasome. The proteasome can exist in several different forms, depending on the exposure of the APC to proinflammatory stimuli (16, 2541). These different forms of the proteasome engender alternate proteolytic activities and consequently produce a different array of peptide precursors for transport into the lumen of the endoplasmic reticulum (ER). Transport of these peptides occurs in an energy-dependent manner through a member of the ATP binding cassette transporter family known as TAP (transporter associated with antigen processing). The loading of these peptides into the binding cleft of nascent class I molecules involves a number of ER-resident chaperones (4245) and is represented in Fig. 2B. Colocalization of a complex of the class I heavy chain-ß2-microglobulin heterodimer with the chaperones ERp57 (a thiol-oxidoreductase), calreticulin, and tapasin (which collectively form a macromolecular assembly associated with maturation of peptide-MHC complexes known as the peptide-loading complex (PLC)) with the TAP facilitates the loading of peptides into the antigen-binding cleft of the class I molecules. In addition, tapasin plays a role in ligand optimization of MHC class I molecules (4649). Once loaded with suitable peptide cargo, the class I molecule is released from the ER, traverses the Golgi network, and is ultimately transported to the cell surface, where the complex is scrutinized by CD8+ T cells.

The Humoral Response: T Cell-B Cell Collaboration Leads to Secretion of Antibodies
In conjunction with a robust cytotoxic response, the generation of an antibody response is essential to the clearance of many pathogens. Like the T cell receptors expressed on the surface of T lymphocytes, antibodies recognize and bind to relatively short peptide sequences in the context of the intact antigen. As such they frequently display conformational dependence for binding, because they recognize molecular surfaces and not extended antigen fragments bound to MHC molecules. Antibody production is controlled by the interaction between CD4+ T helper cells and B cells that express rearranged antigen-specific immunoglobulin on their cell surface. T helper cells recognize MHC class II molecules that are expressed constitutively on specialized APC such as B cells, dendritic cells (DC), and macrophages; however, initial activation of the T helper cells usually occurs through recognition of class II molecules expressed on activated DCs as depicted in Fig. 1.

Class II MHC molecules acquire antigen via a pathway that is mechanistically and physically distinct to that of class I MHC molecules. Class II molecules are composed of two polymorphic polypeptide chains ({alpha} and ß) forming an {alpha}ß heterodimer, which like class I molecules combine to form the binding cleft that accommodates peptide antigen (see Fig. 3A). Class II {alpha} and ß chains are inserted cotranslationally into the lumen of the ER where they associate to form nascent heterodimers (50). These class II {alpha}ß heterodimers are unstable in the absence of bound peptide and are stabilized through association with a chaperone known as invariant chain (Ii). This chaperone facilitates the formation of a multimeric structure consisting of three {alpha}ß heterodimers each associated with an Ii molecule (i.e. (Ii{alpha}B)3) and occludes the peptide-binding cleft, thereby preventing premature binding of endogenous ER-resident peptides to class II molecules. The Ii is also important in trafficking nascent class II molecules to the endocytic route by virtue of a N-terminal sorting signal (51). For antigenic peptides to be able to bind to class II molecules that are resident in the endocytic compartment, Ii must first be degraded to allow access to the antigen-binding cleft. Cathepsin S mediates the proteolysis of the Ii-MHC complex (52), leaving a portion of the Ii (residues 81–104) bound to class II heterodimers. These class II-associated Ii peptides (known as CLIP) demonstrate promiscuous binding to MHC class II alleles and occlude the peptide-binding cleft of these molecules (53, 54). In order to displace CLIP from the class II binding site, antigenic peptides must have a higher binding affinity than CLIP. This peptide exchange is catalyzed by another MHC-encoded gene product HLA DM (54, 55). Antigenic peptides are loaded in specialized intracellular compartments designated MIIC (MHC class II compartments) that arise from the fusion of late endosomes with class II-rich vesicles. These compartments are rich in cathepsins, and this intersection of the endosomal and class II-processing pathways promotes loading of class II molecules with exogenous antigen fragments. The observation that core peptide epitopes exhibit ragged N and C termini by biochemical analysis of MHC class II-bound peptides suggests that N- and C-terminal exopeptidase activities further trim the peptides bound to class II molecules during their transit from MIIC to the cell surface (56). In B cells and Fc receptor-positive cells, uptake of antigen is facilitated by a receptor-mediated endocytosis that enhances processing of specific antigen or immune complexes and subsequent presentation of CD4+ T cell epitopes. Receptor-mediated uptake of antigen by B cells results in the provision of T help and differentiation of the B cells into plasma- or antibody-secreting cells (as depicted in Fig. 1). The class II-processing pathway is summarized in Fig. 3B.



View larger version (29K):
[in this window]
[in a new window]
 
FIG. 3. MHC class II molecular structure and antigen-processing pathway. A, The three-dimensional structure of a class II molecule. The class II {alpha}ß heterodimer acts as a binding platform to which peptide antigen binds (shown in the green space-filling model). Coordinates used to generate this figure represent the murine class II molecule I-Ak complexed to a hen egg lysozyme peptide (accession number 1IAK) (196). B, Class II antigen-processing pathway. Exogenous antigen is taken up by endocytosis and degraded in the early and late endosomes. The late endosome (containing antigenic peptides) fuses with class II-rich transport vesicles (containing class II heterodimers associated with Ii) to form the MIIC compartment. In the MIIC, HLA DM catalyzes the removal of Ii-derived peptide (CLIP) from the antigen-binding cleft of the {alpha}ß heterodimers, facilitating loading with antigenic peptides. This mature class II complex is then transported to the cell surface for scrutiny by CD4+ T helper cells.

 
The mode of binding and repertoire of peptide ligands bound by MHC class II molecules has also been analyzed by biochemical methods and x-ray crystallographic studies (3, 5761) and differs in several ways from the binding of peptides to class I molecules. Peptides that bind to MHC class II molecules are typically longer than class I ligands and tend to average around 13 amino acids in length but can be considerably longer. The interactions that close the peptide-binding cleft of class I molecules are not apparent in class II molecules, allowing the termini of the bound class II peptide to project out of the ends of the cleft. The bound peptide is retained in the cleft of class II molecules by interactions between the side chains of the peptide ligand, the specificity determining pockets of the class II molecule, and a conserved hydrogen-bonding network between the peptide backbone and conserved amino acids of the antigen-binding cleft. Like class I molecules, polymorphic amino acid residues also line the pockets of the binding cleft, and both structural and biochemical studies indicate that amino acid side chains at residues 1, 4, 6, and 9 of the class II-bound peptide typically interact with these pockets, conferring allelic specificity (3) and "anchoring" the peptide into the cleft. It has also been suggested that the binding of ligands to MHC class II molecules is more promiscuous than the binding of peptides to MHC class I molecules due to their free termini and ability to shift binding registers, making it more difficult to define anchor residues and to predict which peptides will be able to bind particular MHC class II molecules.

Thus in summary class I and class II molecules have evolved to display fragments of either endogenous and exogenous antigens to CD8+ and CD4+ T cells, respectively. Each antigen-loading pathway is distinct but share several common features including the use of specialized chaperones to facilitate peptide loading, intracellular trafficking, and quality control of the process. Polymorphism within both class I and class II MHC molecules generates alternate arrays of peptide ligands and alternate targets for T cell-mediated immune responses.


    ROLE OF PROTEOMICS IN STUDYING THE TARGETS OF T CELL IMMUNITY
 TOP
 ABSTRACT
 ROLE OF PROTEOMICS IN...
 REFERENCES
 
Defining and Refining MHC-binding Motifs and Their Use in Bioinformatic Screening Approaches for T Cell Epitope Identification
The biochemical analysis of peptides isolated from mature class I or class II molecules (62) has led to an appreciation of allelic polymorphism and its influence on ligand specificity. These and allied studies have been instrumental in establishing consensus-binding motifs for MHC class I and class II molecules, and listings of certain motifs are conveniently web based (see for example Refs. 63 and 64). These motifs describe the amino acids located at critical positions along the sequence of the antigenic peptide that are responsible for making highly conserved and energetically important contacts with pockets in the binding cleft of the class I and class II molecules. These conserved residues are therefore frequently described as "anchor" residues. The conserved length of class I ligands makes analysis of pooled ligands amenable to Edman analysis. Known also as pool Edman sequencing, these experiments utilize Edman chemistry to identify conserved residues at defined positions of the bound ligands (65). Where particular amino acids are favored in the sequences of the bound ligands, a significant increase in the signal observed for the given anchor amino acid is found in the corresponding cycle of Edman chemistry. Both dominant anchor residues (i.e. where the majority of MHC-bound peptides share a conserved amino acid(s) at a distinct position in the ligand) and preferred or nonpreferred residues can be delineated using this technique as inferred by the abundance or lack of signal for particular amino acids in the various cycles of the Edman analysis (62). This form of analysis is less amenable to the study of class II-bound ligands because of the greater length heterogeneity of their ligands. Although pool sequencing is an excellent tool for assessing major changes in peptide specificity for different MHC alleles, it fails to distinguish between very closely related alleles that may have substantial overlap in bound peptide repertoire. For example, we have recently demonstrated that two HLA B44 alleles share up to 95% of their ligands and only high-resolution peptide mapping studies using mass spectrometry were able to reveal these subtle but functionally important differences in ligand repertoire (66).

MHC binding motifs have been used to successfully predict T cell epitopes; however, this approach is successful in de novo prediction of T cell epitopes in only 50–70% of cases even for well-studied and abundant MHC alleles. Moreover, there are numerous examples of atypical ligands possessing non-motif-based sequences, post-translationally modified ligands, or of the failure of antigen processing to liberate the candidate peptides that restrict predictive algorithms to a subset of T cell epitopes (6776). Furthermore, many T cell responses are focused on one or two immunodominant peptides selected from the numerous potential MHC-ligands encoded within the pathogen genome (77). The participation of so few epitopes limit predictive studies because markers of immunogenicity must take into account not just peptide binding characteristics but also the abundance and density of antigen present on the cell surface, the time of expression of the antigen during the infection or pathological process, correct processing and luminal transport of the epitope, as well as the available T cell repertoire in the host organism. Nonetheless, epitope prediction remains a popular first screening method to identify candidate T cell determinants for subsequent biological validation (7889), and predictive algorithms are frequently combined with in vitro MHC-binding assays to confirm experimentally that the predicted ligands bind to the targeted MHC molecule (80, 90). A more comprehensive approach that allows assessment of natural processing and presentation of candidate epitopes involves the direct biochemical analysis of class I or class II ligands, which has been coined as the immunoproteome (82, 83, 9199).

Discovery of T Cell Epitopes of Relevance to Anti-viral and Anti-tumor Immunity, Transplantation and Autoimmune Disease
Several approaches have been used to isolate naturally processed and presented MHC-bound peptides directly from cells; these include analysis of peptides contained within cell lysates (100102), isolation of peptides directly from the cell surface (103, 104), and immunoaffinity purification of the MHC-peptide complexes from detergent-solubilized cell lysates (65, 105). Each approach has advantages, with the later providing the best chance of epitope identification due to the additional specificity of the immunoaffinity chromatography step and subsequent simplification of the range of cellular peptides isolated. However, each method is based upon common features and assumptions that (i) upon cell lysis, peptides bound to MHC molecules are protected from intracellular and extracellular proteolysis because they are bound to the MHC receptor, and (ii) that treatment with acid dissociates bound peptides from the MHC complexes. The relationship between each approach is represented schematically in Fig. 4, this diagram highlights the variety of approaches that can be taken, and some of them are discussed below.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 4. Schematic representation of processes for isolating MHC-bound peptides. A variety of approaches can be taken to examine peptides bound to MHC molecules, with several optional steps highlighted by the various flow paths of the diagram, allowing additional specificity and purification of the starting material.

 
In the first approach, peptides are extracted from whole-cell lysates following treatment with an aqueous acid solution such as 1% trifluoroacetic acid. The presence of trifluoroacetic acid also aids in the precipitation of larger proteins, leaving a complex mixture of intracellular and extracellular peptides, a proportion of which were bound to and protected by MHC molecules. Typically these preparations are fractionated by reverse-phase high-pressure liquid chromatography (RP-HPLC) and screened with a functional assay to confirm the presence of a particular T cell epitope. These fractions can also be titrated into functional assays to allow relative quantitation of known T cell epitopes extracted from the surface of different cell types (100102). In some circumstances, the peptides are amenable to sequencing of individual components of the fractionated material by mass spectrometry. Fig. 5A demonstrates an example of this approach, where a model tumor epitope was identified in an acid eluate of a murine thymoma that expresses chicken ovalbumin as a transfected gene product and surrogate tumor antigen. In this case, the epitope was already known and T cell clones specific for the SIINFEKL determinant were available to screen RP-HPLC fractions (Fig. 5B). This experiment confirmed that the naturally processed and presented form of the SIINFEKL determinant was predominantly the minimal peptide based on T cell recognition of a RP-HPLC fraction with identical retention time as the minimal synthetic peptide. Moreover, later eluting fractions that represented precursors of this peptide were also apparent in this analysis.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 5. Identification of model determinant SIINFEKL from a lysate of chicken ovalbumin-transfected murine thymoma. The fraction comigrating with synthetic SIINFEKL and highlighted by an arrow (A) contained T cell reactivity as determined by IL-2 secretion in a T cell hybridoma screening assay (B). In addition, some later eluting fractions also displayed activity and may have represented longer precursor peptides of the SIINFEKL epitope.

 
An alternative to the acid lysis method utilizes a nonlytic approach for recovering cell-surface-associated peptides. The cells are washed in an isotonic buffer containing citrate at pH 3.3; the acidic nature of this buffer facilitates dissociation of MHC-bound peptides from the cell surface without affecting cell viability (103). The great advantage of this technique is that the same cells may be harvested daily in an iterative approach for obtaining MHC-bound material. Although the specificity of this process is somewhat better for MHC-bound material than it is from whole-cell lysates, some form of biological assay is again usually necessary to locate the peptide(s) of interest prior to attempting more definitive biochemical characterization.

The use of immunoaffinity chromatography dramatically improves the specificity of the peptide extraction process by incorporating an additional, orthogonal separation step. The use of appropriate monoclonal antibodies allows isolation of a single MHC allele, and some antibodies can even select a subpopulation of MHC molecules with defined molecular or functional properties (43, 106). The use of immunoaffinity chromatography to isolate specific MHC molecules provides the most appropriate material for identifying individual peptide ligands restricted by a known MHC allele. It is also critical to the pool sequencing experiment and peptide repertoire studies that focus on the analysis of ligands derived from a specific MHC molecule.

In all the approaches discussed, the complexity of the eluates/lysates can be reduced by using cell lines that express reduced numbers of MHC alleles. For example, homozygous cell lines express a more limited number of MHC class I or class II alleles (three loci for each class), while mutant cell lines such as C1R express very low levels of endogenous class I molecules but support high-level expression of a single transfected class I molecules (107). The simplified array of MHC molecules present on the surface of such cell lines make them very attractive for examining endogenous peptides presented by individual class I alleles under normal physiological conditions (8, 108110) or during infection (20, 111). Following additional RP-HPLC-based fractionation, individual species can be analyzed by mass spectrometry to examine the molecular diversity of bound peptides and also to sequence individual peptide ligands using tandem MS technologies (4, 5).

Visualizing the Complex Array of Peptides Presented on the Surface of APC
It has been estimated that each class I or class II allele may present as many as 10–100,000 different peptides on the surface of APC, and only a very small proportion of these peptides (1–1,000) need to be specific for T cell recognition (112118). Given that for humans any individual may express up to six different class I (two different allotypes encoded by the HLA A, B, and C loci) and six different class II allotypes (two different allotypes encoded by the HLA DR, DQ, and DP loci), the resultant peptide landscape present on the surface of the APC may be extremely complex. Fortunately this mixture can be resolved by immunoaffinity chromatography thanks to the tremendous efforts that have gone into generating monoclonal antibodies that distinguish between the different allotypes, primarily by the tissue typing and transplantation immunologists. Thus, even though only a subset of the cellular proteome may be represented at the cell surface, because peptides derived from cellular proteins are selectively bound by MHC alleles according to their allelic binding preferences and the physical location of the antigen prior to processing, it still results in a tremendous diversity of peptide ligands. High-resolution and information-rich analytical techniques are therefore required to analyze this information, and visualizing this information has presented significant bioinformatic and technical challenges. Our approach, discussed in detail below, has been to perform multidimensional chromatography followed by off-line matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry. The advantages of this approach is that the molecular complexity of the material can be appreciated as a function of a chromatographic index (in our case this is usually a combination of immunoaffinity chromatography to selectively isolate the MHC allotype of interest and microbore RP-HPLC; Fig. 6A) and the majority of the fractionated material is available for functional assays or for further sequence interrogation using nano liquid chromatography (LC) tandem mass spectrometry (MS/MS) and other mass spectrometry-based technologies. Notably, other groups have performed similar analyses using both MALDI and electrospray ionization (ESI) mass spectrometry of fractionated material (e.g. Refs. 20, 119123) and displayed them in a variety of manners including approximating the LC-MS data to a two-dimensional gel-like format (122). In our approach, we chose to perform a systematic comparison of fractions, and for close examination individual spectra were displayed in a reflection mode (124) whereby the two equivalent spectra are superimposed on the m/z axis but displayed in opposite polarity (see Fig. 6B). In this example, the repertoire of peptides expressed by class I molecules on a human mutant APC (721.220 (125)) both prior to (positive polarity) and subsequent to (negative polarity) transfection with HLA B*2705 were compared. Subsequent multidimensional RP-HPLC of this material allowed a detailed analysis of HLA B*2705-bound ligands, and this approach was extended to study the ligand repertoire of HLA B*2705 molecules expressed in mutant cell lines with defects in their antigen-processing machinery, revealing novel properties of this particular class I molecule and clues to its association with the autoimmune disease ankylosing spondylitis (48).



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 6. Schematic representation of our multi-dimensional chromatography off-line MALDI-TOF analysis of the complex immunoproteome of class I molecules (A), and a comparison of class I-bound peptides isolated from the surface of untransfected parental APC (positive spectra) and HLA B*2705 transfected APC (negative spectra) (B). This analysis was performed using a Bruker Reflex mass spectrometer (Bruker-Franzen Analytik, GMBH, Bremen, Germany) operated exclusively in the reflectron mode as described elsewhere (4, 48, 66, 187). Aliquots of each fraction (1–2 µl or ~1% of the fraction) were mixed with an equal volume of matrix solution ({alpha}-cyano-4-hydroxycinnamic acid (10 mg/ml) in acetonitrile-ethanol 1:1 v/v), spotted uniformly onto a target, and dried for analysis. Replicate analysis and care with sample preparation can ensure high reproducibility and confidence in the differential analysis of class I ligands.

 
Sequencing MHC-bound Peptides
The challenges associated with resolving and sequencing individual peptides from the complex mixture of MHC-bound material is not unique to immunoproteomics. This type of experiment is analogous to the shotgun proteomics-type approaches that generate complex mixtures of tryptic (or other proteolytic) fragments derived from a subset of the cellular proteome (21, 94, 126130). Because MHC-bound peptides frequently have varied termini and the proteolytic specificities that generate them are quite diverse, confident assignment of the peptide sequence can be difficult. Similarly, it is rare to detect peptides derived from the same protein unless the study is related to infection, for example, where target antigen sequences are known or suspected (20, 120, 121, 131). These properties of MHC-bound peptides reduce confidence in their sequence assignments by MS/MS techniques and dictate the requirement for additional screening algorithms in epitope identification strategies. For example, if the binding motif for the given allele is known, this frequently can act as a initial filter for assigning fragmentation spectra derived from immunoaffinity-purified class I MHC molecules. Fig. 7 shows the identification of a prominent peptide derived from immunoaffinity-purified HLA B*4402 molecules (binding motif XEXXXXXXF/Y) by post-source decay (PSD) in MALDI-TOF mass spectrometry and highlights the difficulties associated with the sequence assignment of class I-bound peptides, in that many do not strictly adhere to the canonical binding motifs, lack charged termini, and lack mobile protons to facilitate good fragmentation. In this example, the presence of a proline in the sequence favored internal fragment formation, further complicating sequence assignment using automated methods. In our experience, definitive identification of peptides often requires comparison to the fragmentation "fingerprint" of synthetic versions of the candidate sequence as well as confirmation of identical RP-HPLC retention behavior.



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 7. PSD-MALDI-TOF MS sequencing of a HLA B*4402-restricted T cell epitope. Class I-bound peptides frequently yield incomplete b- and y-series ions, and fragmentation can be dominated by the production of internal ions (regions shaded). As such, we frequently compare the fragmentation behavior of synthetic versions of the candidate epitopes to confirm sequence assignment (positive polarity spectrum). PSD-MALDI-TOF was performed using a Bruker Reflex mass spectrometer (Bruker-Franzen Analytik, GMBH) operated exclusively in the reflectron mode as described elsewhere (197, 198).

 
As proteomics instrumentation becomes more accessible to a more diverse array of researchers, so to do the demands for robust techniques for protein and epitope identification. Our work has principally involved a MALDI-TOF mass spectrometry for repertoire analysis, followed by a combination of PSD-MALDI-TOF and nanoESI-Qq-TOF-MS/MS. Others have used different configurations of instrumentation to achieve the same end point. The use of triple quadrupole, three-dimensional ion trap, and more recently Fourier transform mass spectrometry by the Engelhardt/Hunt and other prominent groups has clearly demonstrated the power of these other techniques for epitope identification and repertoire analysis (6, 9, 16, 18, 68, 75, 110, 114, 115, 122, 132152).

One limitation in analysis of MHC-bound peptides is operator bias in selecting peptides from extremely complex mixtures for MS/MS. Newer technologies, such as the MALDI-TOF-TOF-MS/MS instruments will allow much-higher-throughput analyses in an automated mode. This will enable many more peptide fractions to be analyzed without operator bias and make it possible to use higher-resolution collection of HPLC fractions for analysis. The reduced peptide repertoires of narrower fractions will enhance the potential to characterize many more peptides due to the reduced likelihood of the coincidences of masses of peptides in wide-fraction cuts and a lowered tendency for suppression of ionization of peptides. The flexibility of multiple MS/MS modes of other recently developed MS analyzers involving linear ion trap should also facilitate other aspects of immunoproteomics.

Identification of Epitopes Using Peptide Libraries and Mass Spectrometry
Epitope extraction can be used to identify both B cell and T cell epitopes. In this approach peptide libraries, which may be restricted to the context of the primary sequence of a single antigen or completely random, are probed with a relevant receptor (either antibody or nascent MHC molecules) to allow extraction of ligands (90, 153159). Mass spectrometry is subsequently used to identify the extracted components rather than deconvoluting the library into separate components or using more exhaustive library screening techniques to delineate the chemical structure of the ligand (160165). Here either the antibody is incubated with the peptide library or recombinant MHC molecules are incubated with the library. For example, we recently screened class I molecules for binding to preproinsulin peptides (90). In our approach, nascent MHC class I heavy chain and ß2-microglobulin are assembled in vitro in the presence of libraries of short (8–10 amino acid residues) peptides representing the sequence of preproinsulin. After refolding of the class I molecules within this environment, potential CTL epitopes are captured or extracted from the peptide mixture. The subsequent elution of these extracted peptides from the refolded complexes and identification of bound peptides by mass spectrometry then leads to the identification of all potential class I ligands for any antigen of known sequence. This approach does not bias the epitope search for known binding motifs and is amenable to high throughput using multiple alleles to maximize MHC class I haplotype coverage for inclusion in epitope-based subunit vaccines (166, 167). This form of epitope extraction has also been used to define class I binding motifs in combination with pool Edman sequencing (159, 168).

The specificity and sensitivity of the immune response is unparalleled in biology, and the use of antibodies, for example, as diagnostic and research tools has been commonplace for many years. Proteomic analysis of the peptides and antigens involved in immune responses to pathogens and to abnormal or even normal tissues presents exciting and difficult challenges to the investigator. Underlying all these studies is the power of the immunological reagents and functional readouts that provide exquisite sensitivity unrivalled by the analytical techniques we have at hand. The use of these reagents as screening tools or as a fractionation technique will drive immunoproteomics research in the future. The use of antibodies and recombinant reagents such as MHC-tetramers and other markers of immune effector cells provide opportunities to obtain large numbers of homogeneous cells from tissues and fluids using fractionation or isolation techniques such as flow cytometry and cell sorting and laser capture microscopy. When used in combination with more typical fractionation techniques such as subcellular fractionation and affinity chromatography, the degree to which resolution of specific cells can be isolated and analyzed is improved dramatically.

What are the challenges that lie ahead in immunoproteomics? Well, they are very similar to those for proteomics in general. Significant challenges in bioinformatics and searching algorithms exist for automation of MS/MS sequence assignments. Subsequent to these identification methods, the ability to display the complex array of peptides that comprise the immunoproteome and correlate data from different sources still remains a major obstacle for these studies. The issue of absolute quantitation of MHC-bound peptides using isotope-labeling techniques and so forth needs to be addressed. Finally, sensitivity and sample consumption (moving toward proteomic analysis of biopsy samples) has not fully realized its potential, and techniques such as laser capture microscopy used in tandem with MS are beginning to address these issues particularly in the identification of tumor antigens and biomarkers of malignant disease (169186).


    FOOTNOTES
 
Received, November 27, 2003

Published, MCP Papers in Press, January 8, 2004, DOI 10.1074/mcp.R300013-MCP200

1 The abbreviations used are: APC, antigen-presenting cell; MHC, major histocompatibility complex; CTL, cytotoxic T lymphocyte; ER, endoplasmic reticulum; TAP, transporter associated with antigen processing; PLC, peptide-loading complex; DC, dendritic cell; Ii, invariant chain; CLIP, class II-associated Ii peptide; MIIC, MHC class II compartment; RP-HPLC, reverse-phase high-pressure liquid chromatography; MALDI, matrix-assisted laser desorption/ionization; TOF, time-of-flight; LC, liquid chromatography; MS/MS, tandem mass spectroscopy; ESI, electrospray ionization; PSD, post-source decay. Back

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ To whom correspondence should be addressed. E-mail: apurcell{at}unimelb.edu.au


    REFERENCES
 TOP
 ABSTRACT
 ROLE OF PROTEOMICS IN...
 REFERENCES
 

  1. Matzinger, P. (1994) Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991 –1045[CrossRef][Medline]

  2. Matzinger, P. (1998) An innate sense of danger. Semin. Immunol. 10, 399 –415[CrossRef][Medline]

  3. Rammensee, H. G. (1995) Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7, 85 –96[CrossRef][Medline]

  4. Purcell, A. W., and Gorman, J. J. (2001) The use of post-source decay in matrix-assisted laser desorption/ionisation mass spectrometry to delineate T cell determinants. J. Immunol. Methods 249, 17 –31[CrossRef][Medline]

  5. Bonner, P. L., Lill, J. R., Hill, S., Creaser, C. S., and Rees, R. C. (2002) Electrospray mass spectrometry for the identification of MHC class I-associated peptides expressed on cancer cells. J. Immunol. Methods 262, 5 –19[CrossRef][Medline]

  6. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sacaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V. H. (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261 –1263[Medline]

  7. de Jong, A. (1998) Contribution of mass spectrometry to contemporary immunology. Mass Spectrom. Rev. 17, 311 –335[CrossRef][Medline]

  8. Paradela, A., Garcia-Peydro, M., Vazquez, J., Rognan, D., and Lopez de Castro, J. A. (1998) The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. J. Immunol. 161, 5481 –5490[Abstract/Free Full Text]

  9. Appella, E., Padlan, E. A., and Hunt, D. F. (1995) Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Exs 73, 105 –119[Medline]

  10. Chicz, R. M., Lane, W. S., Robinson, R. A., Trucco, M., Strominger, J. L., and Gorga, J. C. (1994) Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. Int. Immunol. 6, 1639 –1649[Abstract]

  11. Chicz, R. M., Urban, R. G., Lane, W. S., Gorga, J. C., Stern, L. J., Vignali, D. A., and Strominger, J. L. (1992) Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358, 764 –768[CrossRef][Medline]

  12. Engelhard, V. H., Appella, E., Benjamin, D. C., Bodnar, W. M., Cox, A. L., Chen, Y., Henderson, R. A., Huczko, E. L., Michel, H., Sakaguichi, K., et al. (1993) Mass spectrometric analysis of peptides associated with the human class I MHC molecules HLA-A2.1 and HLA-B7 and identification of structural features that determine binding. Chem. Immunol. 57, 39 –62[Medline]

  13. Gugasyan, R., Vidavsky, I., Nelson, C. A., Gross, M. L., and Unanue, E. R. (1998) Isolation and quantitation of a minor determinant of hen egg white lysozyme bound to I-Ak by using peptide-specific immunoaffinity. J. Immunol. 161, 6074 –6083[Abstract/Free Full Text]

  14. Joyce, S., and Nathenson, S. G. (1994) Methods to study peptides associated with MHC class I molecules. Curr. Opin. Immunol. 6, 24 –31[CrossRef][Medline]

  15. Kropshofer, H., Vogt, A. B., Moldenhauer, G., Hammer, J., Blum, J. S., and Hammerling, G. J. (1996) Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15, 6144 –6154[Abstract]

  16. Luckey, C. J., King, G. M., Marto, J. A., Venketeswaran, S., Maier, B. F., Crotzer, V. L., Colella, T. A., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (1998) Proteasomes can either generate or destroy MHC class I epitopes: Evidence for nonproteasomal epitope generation in the cytosol. J. Immunol. 161, 112 –121[Abstract/Free Full Text]

  17. Prilliman, K. R., Jackson, K. W., Lindsey, M., Wang, J., Crawford, D., and Hildebrand, W. H. (1999) HLA-B15 peptide ligands are preferentially anchored at their C termini. J. Immunol. 162, 7277 –7284[Abstract/Free Full Text]

  18. Skipper, J. C., Gulden, P. H., Hendrickson, R. C., Harthun, N., Caldwell, J. A., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. (1999) Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82, 669 –677[CrossRef][Medline]

  19. Sudo, T., Kamikawaji, N., Kimura, A., Date, Y., Savoie, C. J., Nakashima, H., Furuichi, E., Kuhara, S., and Sasazuki, T. (1995) Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J. Immunol. 155, 4749 –4756[Abstract]

  20. van Els, C. A., Herberts, C. A., van der Heeft, E., Poelen, M. C., van Gaans-van den Brink, J. A., van der Kooi, A., Hoogerhout, P., Jan ten Hove, G., Meiring, H. D., and de Jong, A. P. (2000) A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30, 1172 –1181[CrossRef][Medline]

  21. Admon, A., Barnea, E., and Ziv, T. (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2, 388 –398[Abstract/Free Full Text]

  22. Lemmel, C., and Stevanovic, S. (2003) The use of HPLC-MS in T-cell epitope identification. Methods 29, 248 –259[CrossRef][Medline]

  23. Barnea, E., Beer, I., Patoka, R., Ziv, T., Kessler, O., Tzehoval, E., Eisenbach, L., Zavazava, N., and Admon, A. (2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: A novel approach for identifying tumor-specific antigens. Eur. J. Immunol. 32, 213 –222[CrossRef][Medline]

  24. Creaser, C. S., Lill, J. R., Bonner, P. L., Hill, S. C., and Rees, R. C. (2000) Nano-electrospray and microbore liquid chromatography-ion trap mass spectrometry studies of copper complexation with MHC restricted peptides. Analyst 125, 599 –603[CrossRef][Medline]

  25. Kuckelkorn, U., Ferreira, E. A., Drung, I., Liewer, U., Kloetzel, P. M., and Theobald, M. (2002) The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur. J. Immunol. 32, 1368 –1375[CrossRef][Medline]

  26. Kuckelkorn, U., Ruppert, T., Strehl, B., Jungblut, P. R., Zimny-Arndt, U., Lamer, S., Prinz, I., Drung, I., Kloetzel, P. M., Kaufmann, S. H., and Steinhoff, U. (2002) Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J. Exp. Med. 195, 983 –990[Abstract/Free Full Text]

  27. Rivett, A. J., Bose, S., Brooks, P., and Broadfoot, K. I. (2001) Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 83, 363 –366[CrossRef][Medline]

  28. Groettrup, M., Khan, S., Schwarz, K., and Schmidtke, G. (2001) Interferon-gamma inducible exchanges of 20S proteasome active site subunits: Why? Biochimie 83, 367 –372[CrossRef][Medline]

  29. Chen, W., Norbury, C. C., Cho, Y., Yewdell, J. W., and Bennink, J. R. (2001) Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 193, 1319 –1326[Abstract/Free Full Text]

  30. Rechsteiner, M., Realini, C., and Ustrell, V. (2000) The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 345 (Pt 1), 1 –15[Medline]

  31. van Endert, P. M. (1999) Genes regulating MHC class I processing of antigen. Curr. Opin. Immunol. 11, 82 –88[CrossRef][Medline]

  32. Niedermann, G., Geier, E., Lucchiari-Hartz, M., Hitziger, N., Ramsperger, A., and Eichmann, K. (1999) The specificity of proteasomes: Impact on MHC class I processing and presentation of antigens. Immunol. Rev. 172, 29 –48[Medline]

  33. Preckel, T., Fung-Leung, W. P., Cai, Z., Vitiello, A., Salter-Cid, L., Winqvist, O., Wolfe, T. G., Von Herrath, M., Angulo, A., Ghazal, P., Lee, J. D., Fourie, A. M., Wu, Y., Pang, J., Ngo, K., Peterson, P. A., Fruh, K., and Yang, Y. (1999) Impaired immunoproteasome assembly and immune responses in PA28-/- mice. Science 286, 2162 –2165[Abstract/Free Full Text]

  34. Pryhuber, K. G., Murray, K. J., Donnelly, P., Passo, M. H., Maksymowych, W. P., Glass, D. N., Giannini, E. H., and Colbert, R. A. (1996) Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. J. Rheumatol. 23, 747 –752[Medline]

  35. Nandi, D., Jiang, H., and Monaco, J. J. (1996) Identification of MECL-1 (LMP-10) as the third IFN-{gamma}-inducible proteasome subunit. J. Immunol. 156, 2361 –2364[Abstract]

  36. Groettrup, M., Soza, A., Eggers, M., Kuehn, L., Dick, T. P., Schild, H., Rammensee, H. G., Koszinowski, U. H., and Kloetzel, P. M. (1996) A role for the proteasome regulator PA28alpha in antigen presentation. Nature 381, 166 –168[CrossRef][Medline]

  37. Momburg, F., Ortiz-Navarrete, V., Neefjes, J., Goulmy, E., van de Wal, Y., Spits, H., Powis, S. J., Butcher, G. W., Howard, J. C., Walden, P., et al. (1992) Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 360, 174 –177[CrossRef][Medline]

  38. Chu-Ping, M., Willy, P. J., Slaughter, C. A., and Martino, G. N. (1993) PN28, an activator of the 20S proteasome, is inactivated by proteolytic modification at its carboxyl terminus. J. Biol. Chem. 268, 22514 –22519[Abstract/Free Full Text]

  39. Gray, C. W., Slaughter, C. A., and DeMartino, G. N. (1994) PA28 activator protein forms regulatory caps on proteasome stacked rings. J. Mol. Biol. 236, 7 –15[CrossRef][Medline]

  40. Yewdell, J., Lapham, C., Bacik, I., Spies, T., and Bennink, J. (1994) MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J. Immunol. 152, 1163 –1170[Abstract/Free Full Text]

  41. Groettrup, M., Ruppert, T., Kuehn, L., Seeger, M., Standera, S., Koszinowski, U., and Kloetzel, P. M. (1995) The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. Biol. Chem. 270, 23808 –23815[Abstract/Free Full Text]

  42. Cresswell, P., Bangia, N., Dick, T., and Diedrich, G. (1999) The nature of the MHC class I peptide loading complex. Immunol. Rev. 172, 21 –28[Medline]

  43. Purcell, A. W. (2000) The peptide-loading complex and ligand selection during the assembly of HLA class I molecules. Mol. Immunol. 37, 483 –492[CrossRef][Medline]

  44. Williams, A., Peh, C. A., and Elliott, T. (2002) The cell biology of MHC class I antigen presentation. Tissue Antigens 59, 3 –17[CrossRef][Medline]

  45. Momburg, F., and Tan, P. (2002) Tapasin—The keystone of the loading complex optimizing peptide binding by MHC class I molecules in the endoplasmic reticulum. Mol. Immunol. 39, 217[CrossRef][Medline]

  46. Schoenhals, G. J., Krishna, R. M., Grandea, A. G., Spies, T., Peterson, P. A., Yang, Y., and Fruh, K. (1999) Retention of empty MHC class I molecules by tapasin is essential to reconstitute antigen presentation in invertebrate cells. EMBO J. 18, 743 –753[Abstract/Free Full Text]

  47. Barnden, M. J., Purcell, A. W., Gorman, J. J., and McCluskey, J. (2000) Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J. Immunol. 165, 322 –330[Abstract/Free Full Text]

  48. Purcell, A. W., Gorman, J. J., Garcia-Peydro, M., Paradela, A., Burrows, S. R., Talbo, G. H., Laham, N., Peh, C. A., Reynolds, E. C., Lopez De Castro, J. A., and McCluskey, J. (2001) Quantitative and qualitative influences of tapasin on the class I peptide repertoire. J. Immunol. 166, 1016 –1027[Abstract/Free Full Text]

  49. Williams, A. P., Peh, C. A., Purcell, A. W., McCluskey, J., and Elliott, T. (2002) Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 16, 509 –520[Medline]

  50. Arunachalam, B., and Cresswell, P. (1995) Molecular requirements for the interaction of class II major histocompatibility complex molecules and invariant chain with calnexin. J. Biol. Chem. 270, 2784 –2790[Abstract/Free Full Text]

  51. Germain, R. N., Castellino, F., Han, R., Reis e Sousa, C., Romagnoli, P., Sadegh-Nasseri, S., and Zhong, G. M. (1996) Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol. Rev. 151, 5 –30[Medline]

  52. Villadangos, J. A. (2001) Presentation of antigens by MHC class II molecules: getting the most out of them. Mol. Immunol. 38, 329 –346[CrossRef][Medline]

  53. Weenink, S. M., and Gautam, A. M. (1997) Antigen presentation by MHC class II molecules. Immunol. Cell. Biol. 75, 69 –81[Medline]

  54. Jensen, P. E., Weber, D. A., Thayer, W. P., Chen, X., and Dao, C. T. (1999) HLA-DM and the MHC class II antigen presentation pathway. Immunol. Res. 20, 195 –205[Medline]

  55. Denzin, L. K., and Cresswell, P. (1995) HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 82, 155 –165[Medline]

  56. Watts, C. (1997) Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15, 821 –850[CrossRef][Medline]

  57. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G. (1994) Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 39, 230 –242[Medline]

  58. Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33 –39[CrossRef][Medline]

  59. Reinherz, E. L., Tan, K., Tang, L., Kern, P., Liu, J., Xiong, Y., Hussey, R. E., Smolyar, A., Hare, B., Zhang, R., Joachimiak, A., Chang, H. C., Wagner, G., and Wang, J. (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286, 1913 –1921[Abstract/Free Full Text]

  60. Scott, C. A., Peterson, P. A., Teyton, L., and Wilson, I. A. (1998) Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 8, 319 –329[Medline]

  61. Fremont, D. H., Hendrickson, W. A., Marrack, P., and Kappler, J. (1996) Structures of an MHC class II molecule with covalently bound single peptides. Science 272, 1001 –1004[Abstract]

  62. Rammensee, H.-G., Friede, T., and Stevanovic, S. (1995) MHC ligands and peptide motifs: First listing. Immunogenetics 41, 178 –228[Medline]

  63. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S. (1999) SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50, 213 –219 (syfpeithi.bmi-heidelberg.com)[CrossRef][Medline]

  64. Parker, K. C., Bednarek, M. A., and Coligan, J. E. (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163 –175 (www-bimas.dcrt.nih.gov/molbio/hla_bind/)[Abstract/Free Full Text]

  65. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H.-G. (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290 –296[CrossRef][Medline]

  66. Macdonald, W. A., Purcell, A. W., Mifsud, N., Ely, L. K., Williams, D. S., Chang, L., Gorman, J. J., Clements, C. S., Kjer-Nielsen, L., Koelle, D. M., Burrows, S. R., Tait, B. D., Holdsworth, R., Brooks, A. G., Lovrecz, G. O., Lu, L., Rossjohn, J., and McCluskey, J. (2003) A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire and T cell recognition. J. Exp. Med. 198, 679 –691[Abstract/Free Full Text]

  67. Andersen, M. H., Bonfill, J. E., Neisig, A., Arsequell, G., Sondergaard, I., Neefjes, J., Zeuthen, J., Elliott, T., and Haurum, J. S. (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific. CTL J. Immunol. 163, 3812 –3818[Abstract/Free Full Text]

  68. Chen, Y., Sidney, J., Southwood, S., Cox, A. L., Sakaguchi, K., Henderson, R. A., Appella, E., Hunt, D. F., Sette, A., and Engelhard, V. H. (1994) Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152, 2874 –2881[Abstract/Free Full Text]

  69. Chen, W., Ede, N. J., Jackson, D. C., McCluskey, J., and Purcell, A. W. (1996) CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 157, 1000 –1005[Abstract]

  70. Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y., Dwek, R. A., McMichael, A. J., and Elliott, T. (1994) Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180, 739 –744[Abstract]

  71. Kohler, J., Martin, S., Pflugfelder, U., Ruh, H., Vollmer, J., and Weltzien, H. U. (1995) Cross-reactive trinitrophenylated peptides as antigens for class II major histocompatibility complex-restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire. Eur. J. Immunol. 25, 92 –101[Medline]

  72. Martin, S., Ruh, H., Hebbelmann, S., Pflugfelder, U., Rude, B., and Weltzien, H. U. (1995) Carrier-reactive hapten-specific cytotoxic T lymphocyte clones originate from a highly preselected T cell repertoire: Implications for chemical-induced self-reactivity. Eur. J. Immunol. 25, 2788 –2796[Medline]

  73. Moulon, C., Vollmer, J., and Weltzien, H. U. (1995) Characterization of processing requirements and metal cross-reactivities in T cell clones from patients with allergic contact dermatitis to nickel. Eur. J. Immunol. 25, 3308 –3315[Medline]

  74. Purcell, A. W., Chen, W., Ede, N. J., Gorman, J. J., Fecondo, J. V., Jackson, D. C., Zhao, Y., and McCluskey, J. (1998) Avoidance of self-reactivity results in skewed CTL responses to rare components of synthetic immunogens. J. Immunol. 160, 1085 –1090[Abstract/Free Full Text]

  75. Skipper, J. C. A., Hendrickson, R. C., Gulden, P. H., Brichard, V., Vanpel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., Hunt, D. F., and Engelhard, V. H. (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med. 183, 527 –534[Abstract]

  76. Eisenlohr, L. C., Yewdell, J. W., and Bennink, J. R. (1992) Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J. Exp. Med. 175, 481 –487[Abstract]

  77. Yewdell, J. W., and Bennink, J. R. (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51 –88[CrossRef][Medline]

  78. van-der-Burg, S. H., Klein, M. R., van-de-Velde, C. J., Kast, W. M., Miedema, F., and Melief, C. J. (1995) Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. AIDS 9, 121 –127[Medline]

  79. Feller, D. C., and de la Cruz, V. F. (1991) Identifying antigenic T-cell sites. Nature 349, 720 –721[CrossRef][Medline]

  80. Andersen, M. H., Tan, L., Sondergaard, I., Zeuthen, J., Elliott, T., and Haurum, J. S. (2000) Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55, 519 –531[CrossRef][Medline]

  81. Schirle, M., Weinschenk, T., and Stevanovic, S. (2001) Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens J. Immunol. Methods 257, 1 –16[CrossRef][Medline]

  82. Maecker, B., von, B.-B., Anderson, K. S., Vonderheide, R. H., and Schultze, J. L. (2001) Linking genomics to immunotherapy by reverse immunology—"Immunomics" in the new millennium. Curr. Mol. Med. 1, 609 –619[Medline]

  83. Ristori, G., Salvetti, M., Pesole, G., Attimonelli, M., Buttinelli, C., Martin, R., and Riccio, P. (2000) Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens. FASEB J. 14, 431 –438[Abstract/Free Full Text]

  84. Verginis, P., Stanford, M. M., and Carayanniotis, G. (2002) Delineation of five thyroglobulin T cell epitopes with pathogenic potential in experimental autoimmune thyroiditis. J. Immunol. 169, 5332 –5337[Abstract/Free Full Text]

  85. Lu, J., and Celis, E. (2000) Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res. 60, 5223 –5227[Abstract/Free Full Text]

  86. Schafer, J. R., Jesdale, B. M., George, J. A., Kouttab, N. M., and De Groot, A. S. (1998) Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix Vaccine 16, 1880 –1884[CrossRef]

  87. Brusic, V., Rudy, G., Honeyman, G., Hammer, J., and Harrison, L. (1998) Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 14, 121 –130[Abstract]

  88. Roberts, C. G., Meister, G. E., Jesdale, B. M., Lieberman, J., Berzofsky, J. A., and De Groot, A. S. (1996) Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res. Hum. Retroviruses 12, 593 –610[Medline]

  89. Meister, G. E., Roberts, C. G., Berzofsky, J. A., and De Groot, A. S. (1995) Two novel T cell epitope prediction algorithms based on MHC-binding motifs: Comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13, 581 –591[CrossRef][Medline]

  90. Chang, L., Kjer-Nielsen, L., Flynn, S., Brooks, A. G., Mannering, S. I., Honeyman, M. C., Harrison, L. C., McCluskey, J., and Purcell, A. W. (2003) A method for identification of candidate cytotoxic T cell epitopes: Evaluation of HLA-class I ligands from human preproinsulin. Tissue Antigens 62, 408 –417[CrossRef][Medline]

  91. Zijlstra, A., Testa, J. E., and Quigley, J. P. (2003) Targeting the proteome/epitome, implementation of subtractive immunization. Biochem. Biophys. Res. Commun. 303, 733 –744[CrossRef][Medline]

  92. Ballot, E., Bruneel, A., Labas, V., and Johanet, C. (2003) Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin. Chem. 49, 634 –643[Abstract/Free Full Text]

  93. Bumann, D., Holland, P., Siejak, F., Koesling, J., Sabarth, N., Lamer, S., Zimny-Arndt, U., Jungblut, P. R., and Meyer, T. F. (2002) A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening. Infect. Immun. 70, 6494 –6498[Abstract/Free Full Text]

  94. Klade, C. S. (2002) Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4, 216 –223[Medline]

  95. Haas, G., Karaali, G., Ebermayer, K., Metzger, W. G., Lamer, S., Zimny-Arndt, U., Diescher, S., Goebel, U. B., Vogt, K., Roznowski, A. B., Wiedenmann, B. J., Meyer, T. F., Aebischer, T., and Jungblut, P. R. (2002) Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2, 313 –324[CrossRef][Medline]

  96. Shalhoub, P., Kern, S., Girard, S., and Beretta, L. (2001) Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis. Markers 17, 217 –223[Medline]

  97. Thery, C., Boussac, M., Veron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., and Amigorena, S. (2001) Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 166, 7309 –7318[Abstract/Free Full Text]

  98. Romer, T. G., and Boyle, M. D. (2003) Application of immunoproteomics to analysis of post-translational processing of the antiphagocytic M protein of Streptococcus. Proteomics 3, 29 –35[CrossRef][Medline]

  99. Jungblut, P. R. (2001) Proteome analysis of bacterial pathogens. Microbes Infect. 3, 831 –840[CrossRef][Medline]

  100. Falk, K., Rötzschke, O., Deres, K., Metzger, J., Jung, G., and Rammensee, H.-G. (1991) Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast. J. Exp. Med. 174, 425 –434[Abstract]

  101. Sijts, A. J., Neisig, A., Neefjes, J., and Pamer, E. G. (1996) Two Listeria monocytogenes CTL epitopes are processed from the same antigen with different efficiencies. J. Immunol. 156, 683 –692[Abstract]

  102. Rotzschke, O., Falk, K., Deres, K., Schild, H., Norda, M., Metzger, J., Jung, G., and Rammensee, H. G. (1990) Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348, 252 –254[CrossRef][Medline]

  103. Storkus, W. J., Zeh, H. J., Salter, R. D., and Lotze, M. T. (1993) Identification of T-cell epitopes: Rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. 14, 94 –103[Medline]

  104. Storkus, W. J., Zeh, H. J., Maeurer, M. J., Salter, R. D., and Lotze, M. T. (1993) Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol. 151, 3719 –3727[Abstract/Free Full Text]

  105. Rammensee, H. G., Falk, K., and Rotzschke, O. (1993) Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11, 213 –244[CrossRef][Medline]

  106. Urban, R. G., Chicz, R. M., Lane, W. S., Strominger, J. L., Rehm, A., Kenter, M. J., UytdeHaag, F. G., Ploegh, H., Uchanska-Ziegler, B., and Ziegler, A. (1994) A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc. Natl. Acad. Sci. U. S. A. 91, 1534 –1538[Abstract]

  107. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., and Cresswell, P. (1987) NK susceptibility varies inversely with target cell class I HLA antigen expression J. Immunol. 138, 1657 –1659[Free Full Text]

  108. Boisgerault, F., Tieng, V., Stolzenberg, M. C., Dulphy, N., Khalil, I., Tamouza, R., Charron, D., and Toubert, A. (1996) Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies J. Clin. Invest. 98, 2764 –2770[Abstract/Free Full Text]

  109. Fruci, D., Butler, R. H., Greco, G., Rovero, P., Pazmany, L., Vigneti, E., Tosi, R., and Tanigaki, N. (1995) Differences in peptide-binding specificity of two ankylosing spondylitis-associated HLA-B27 subtypes. Immunogenetics 42, 123 –128[Medline]

  110. Skipper, J. C., Kittlesen, D. J., Hendrickson, R. C., Deacon, D. D., Harthun, N. L., Wagner, S. N., Hunt, D. F., Engelhard, V. H., and Slingluff, C. L., Jr. (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 157, 5027 –5033[Abstract]

  111. Ringrose, J. H., Yard, B. A., Muijsers, A., Boog, C. J., and Feltkamp, T. E. (1996) Comparison of peptides eluted from the groove of HLA-B27 from Salmonella infected and non-infected cells. Clin. Rheumatol. 15 (Suppl. 1), 74 –78[Medline]

  112. Sette, A., Sidney, J., del Guercio, M. F., Southwood, S., Ruppert, J., Dahlberg, C., Grey, H. M., and Kubo, R. T. (1994) Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31, 813 –822[CrossRef][Medline]

  113. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. M., Oseroff, C., Yuan, L., Ruppert, J., Sidney, J., Delguercio, M. F., Southwood, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Chisari, F. V. (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586 –5592[Abstract/Free Full Text]

  114. Sette, A., DeMars, R., Grey, H. M., Oseroff, C., Southwood, S., Appella, E., Kubo, R. T., and Hunt, D. F. (1993) Isolation and characterization of naturally processed peptides bound by class II molecules and peptides presented by normal and mutant antigen-presenting cells. Chem. Immunol. 57, 152 –165[Medline]

  115. Crotzer, V. L., Christian, R. E., Brooks, J. M., Shabanowitz, J., Settlage, R. E., Marto, J. A., White, F. M., Rickinson, A. B., Hunt, D. F., and Engelhard, V. H. (2000) Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J. Immunol. 164, 6120 –6129[Abstract/Free Full Text]

  116. Christinck, E. R., Luscher, M. A., Barber, B. H., and Williams, D. B. (1991) Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352, 67 –70[CrossRef][Medline]

  117. Demotz, S., Grey, H. M., and Sette, A. (1990) The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 249, 1028 –1030[Medline]

  118. Harding, C. V., and Unanue, E. R. (1990) Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 346, 574 –576[CrossRef][Medline]

  119. Gregers, T. F., Fleckenstein, B., Vartdal, F., Roepstorff, P., Bakke, O., and Sandlie, I. (2003) MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Int. Immunol. 15, 1291 –1299[Abstract/Free Full Text]

  120. Herberts, C. A., Stittelaar, K. J., van der Heeft, E., van Gaans-Van den Brink, J., Poelen, M. C., Roholl, P. J., van Alphen, L. J., Melief, C. J., de Jong, A. P., and van Els, C. A. (2001) A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. J. Gen. Virol. 82, 2131 –2142[Abstract/Free Full Text]

  121. Herberts, C. A., van Gaans-van den Brink, J., van der Heeft, E., van Wijk, M., Hoekman, J., Jaye, A., Poelen, M. C., Boog, C. J., Roholl, P. J., Whittle, H., de Jong, A. P., and van Els, C. C. (2003) Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection. Hum. Immunol. 64, 44 –55[Medline]

  122. Luckey, C. J., Marto, J. A., Partridge, M., Hall, E., White, F. M., Lippolis, J. D., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2001) Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J. Immunol. 167, 1212 –1221[Abstract/Free Full Text]

  123. Hickman, H. D., Luis, A. D., Bardet, W., Buchli, R., Battson, C. L., Shearer, M. H., Jackson, K. W., Kennedy, R. C., and Hildebrand, W. H. (2003) Cutting edge: Class I presentation of host peptides following HIV infection. J. Immunol. 171, 22 –26[Abstract/Free Full Text]

  124. Spengler, B., Kirsch, D., Kaufmann, R., and Jaeger, E. (1993) Peptide sequencing by matrix-assisted laser-desorption mass spectrometry. Rapid Commun. Mass Spectrom. 6, 105 –108

  125. DeMars, R., Rudersdorf, R., Chang, C., Petersen, J., Strandtmann, J., Korn, N., Sidwell, B., and Orr, H. T. (1985) Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc. Natl. Acad. Sci. U. S. A. 82, 8183 –8187[Abstract]

  126. Yates, J. R., 3rd (2000) Mass spectrometry. From genomics to proteomics. Trends Genet. 16, 5 –8[CrossRef][Medline]

  127. Wolters, D. A., Washburn, M. P., and Yates, J. R., 3rd (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal. Chem. 73, 5683 –5690[CrossRef][Medline]

  128. Mann, M., Hendrickson, R. C., and Pandey, A. (2001) Analysis of proteins and proteomes by mass spectrometry. Annu. Rev. Biochem. 70, 437 –473[CrossRef][Medline]

  129. Gygi, S. P., and Aebersold, R. (2000) Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 4, 489 –494[CrossRef][Medline]

  130. Gevaert, K., and Vandekerckhove, J. (2000) Protein identification methods in proteomics. Electrophoresis 21, 1145 –1154[CrossRef][Medline]

  131. van der Heeft, E., ten Hove, G. J., Herberts, C. A., Meiring, H. D, van Els, C. A., and de Jong, A. P. (1998) A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules. Anal. Chem. 70, 3742 –3751[CrossRef][Medline]

  132. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716 –719[Medline]

  133. Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., and Engelhard, V. H. (1992) HLA-A2.1-associated peptides from a mutant cell line: A second pathway of antigen presentation. Science 255, 1264 –1266[Medline]

  134. Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M., and Sette, A. (1992) Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256, 1817 –1820[Medline]

  135. Sette, A., Ceman, S., Kubo, R. T., Sakaguchi, K., Appella, E., Hunt, D. F., Davis, T. A., Michel, H., Shabanowitz, J., Rudersdorf, R., et al. (1992) Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. Science 258, 1801 –1804[Medline]

  136. Henderson, R. A., Cox, A. L., Sakaguchi, K., Appella, E., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (1993) Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 90, 10275 –10279[Abstract]

  137. Huczko, E. L., Bodnar, W. M., Benjamin, D., Sakaguchi, K., Zhu, N. Z., Shabanowitz, J., Henderson, R. A., Appella, E., Hunt, D. F., and Engelhard, V. H. (1993) Characteristics of endogenous peptides eluted from the class I MHC molecule HLA-B7 determined by mass spectrometry and computer modeling. J. Immunol. 151, 2572 –2587[Abstract/Free Full Text]

  138. Slingluff, C. L., Jr., Cox, A. L., Henderson, R. A., Hunt, D. F., and Engelhard, V. H. (1993) Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 150, 2955 –2963[Abstract/Free Full Text]

  139. Slingluff, C. L., Jr., Hunt, D. F., and Engelhard, V. H. (1994) Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol. 6, 733 –740[CrossRef][Medline]

  140. Slingluff, C. L., Jr., Cox, A. L., Stover, J. M., Jr., Moore, M. M., Hunt, D. F., and Engelhard, V. H. (1994) Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: Epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res. 54, 2731 –2737[Abstract]

  141. den Haan, J. M., Sherman, N. E., Blokland, E., Huczko, E., Koning, F., Drijfhout, J. W., Skipper, J., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., et al. (1995) Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268, 1476 –1480[Medline]

  142. den Haan, J. M., Bontrop, R. E., Pool, J., Sherman, N., Blokland, E., Engelhard, V. H., Hunt, D. F., and Goulmy, E. (1996) Conservation of minor histocompatibility antigens between human and non-human primates. Eur. J. Immunol. 26, 2680 –2685[Medline]

  143. Fiorillo, M. T., Meadows, L., D’Amato, M., Shabanowitz, J., Hunt, D. F., Appella, E., and Sorrentino, R. (1997) Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur. J. Immunol. 27, 368 –373[Medline]

  144. Hu, Q., Bazemore Walker, C. R., Girao, C., Opferman, J. T., Sun, J., Shabanowitz, J., Hunt, D. F., and Ashton-Rickardt, P. G. (1997) Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. Immunity 7, 221 –231[Medline]

  145. Meadows, L., Wang, W., den Haan, J. M., Blokland, E., Reinhardus, C., Drijfhout, J. W., Shabanowitz, J., Pierce, R., Agulnik, A. I., Bishop, C. E., Hunt, D. F., Goulmy, E., and Engelhard, V. H. (1997) The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6, 273 –281[Medline]

  146. Kittlesen, D. J., Thompson, L. W., Gulden, P. H., Skipper, J. C., Colella, T. A., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., Slingluff, C. L., Jr., and Shabanowitz, J. A. (1998) Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development [Published erratum appears in J. Immunol. 1999 162, 3106]. J. Immunol. 160, 2099 –2106[Abstract/Free Full Text]

  147. Zarling, A. L., Ficarro, S. B., White, F. M., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2000) Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192, 1755 –1762[Abstract/Free Full Text]

  148. Guimezanes, A., Barrett-Wilt, G. A., Gulden-Thompson, P., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., Schmitt-Verhulst, A. M., and Engelhardt, V. H. (2001) Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: Distinct characteristics correlated with CD8 dependence. Eur. J. Immunol. 31, 421 –432[CrossRef][Medline]

  149. Nepom, G. T., Lippolis, J. D., White, F. M., Masewicz, S., Marto, J. A., Herman, A., Luckey, C. J., Falk, B., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., and Nepom, B. S. (2001) Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc. Natl. Acad. Sci. U. S. A. 98, 1763 –1768[Abstract/Free Full Text]

  150. Pierce, R. A., Field, E. D., Mutis, T., Golovina, T. N., Von Kap-Herr, C., Wilke, M., Pool, J., Shabanowitz, J., Pettenati, M. J., Eisenlohr, L. C., Hunt, D. F., Goulmy, E., and Engelhard, V. H. (2001) The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167, 3223 –3230[Abstract/Free Full Text]

  151. Lippolis, J. D., White, F. M., Marto, J. A., Luckey, C. J., Bullock, T. N., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (2002) Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets. J. Immunol. 169, 5089 –5097[Abstract/Free Full Text]

  152. Seamons, A., Sutton, J., Bai, D., Baird, E., Bonn, N., Kafsack, B. F., Shabanowitz, J., Hunt, D. F., Beeson, C., and Goverman, J. (2003) Competition between two MHC binding registers in a single peptide processed from myelin basic protein influences tolerance and susceptibility to autoimmunity. J. Exp. Med. 197, 1391 –1397[Abstract/Free Full Text]

  153. Suckau, D., Kohl, J., Karwath, G., Schneider, K., Casaretto, M., Bitter-Suermann, D., and Przybylski, M. (1990) Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping. Proc. Natl. Acad. Sci. U. S. A. 87, 9848 –9852[Abstract]

  154. Parker, C. E., and Tomer, K. B. (2000) Epitope mapping by a combination of epitope excision and MALDI-MS. Methods Mol. Biol. 146, 185 –201[Medline]

  155. Parker, C. E., Papac, D. I., Trojak, S. K., and Tomer, K. B. (1996) Epitope mapping by mass spectrometry: Determination of an epitope on HIV-1 IIIB p26 recognized by a monoclonal antibody. J. Immunol. 157, 198 –206[Abstract]

  156. Hochleitner, E. O., Borchers, C., Parker, C., Bienstock, R. J., and Tomer, K. B. (2000) Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis. Protein Sci. 9, 487 –496[Abstract]

  157. Hochleitner, E. O., Gorny, M. K., Zolla-Pazner, S., and Tomer, K. B. (2000) Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A. J. Immunol. 164, 4156 –4161[Abstract/Free Full Text]

  158. Stevens, J., Wiesmuller, K. H., Butcher, G. W., and Joly, E. (2000) Analysis of peptide length preference of the rat MHC class Ia molecule RT1-A(u), by a modified random peptide library approach. Int. Immunol. 12, 83 –89[Abstract/Free Full Text]

  159. Stevens, J., and Butcher, G. W. (2001) Random peptide libraries. A tool for analyzing peptide specificity of major histocompatibility complex class I molecules. Methods Mol. Biol. 156, 187 –199[Medline]

  160. Davenport, M. P., Smith, K. J., Barouch, D., Reid, S. W., Bodnar, W. M., Willis, A. C., Hunt, D. F., and Hill, A. V. (1997) HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J. Exp. Med. 185, 367 –371[Abstract/Free Full Text]

  161. Pinilla, C., Martin, R., Gran, B., Appel, J. R., Boggiano, C., Wilson, D. B., and Houghten, R. A. (1999) Exploring immunological specificity using synthetic peptide combinatorial libraries. Curr. Opin. Immunol. 11, 193 –202[CrossRef][Medline]

  162. Rubio-Godoy, V., Pinilla, C., Dutoit, V., Borras, E., Simon, R., Zhao, Y., Cerottini, J. C., Romero, P., Houghten, R., and Valmori, D. (2002) Toward synthetic combinatorial peptide libraries in positional scanning format (PS-SCL)-based identification of CD8+ tumor-reactive T-cell ligands: A comparative analysis of PS-SCL recognition by a single tumor-reactive CD8+ cytolytic T-lymphocyte clone. Cancer Res. 62, 2058 –2063[Abstract/Free Full Text]

  163. Zhao, Y., Gran, B., Pinilla, C., Markovic-Plese, S., Hemmer, B., Tzou, A., Whitney, L. W., Biddison, W. E., Martin, R., and Simon, R. (2001) Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J. Immunol. 167, 2130 –2141[Abstract/Free Full Text]

  164. Wiesmuller, K. H., Fleckenstein, B., and Jung, G. (2001) Peptide vaccines and peptide libraries. Biol. Chem. 382, 571 –579[Medline]

  165. Wilson, D. B., Pinilla, C., Wilson, D. H., Schroder, K., Boggiano, C., Judkowski, V., Kaye, J., Hemmer, B., Martin, R., and Houghten, R. A. (1999) Immunogenicity. I. Use of peptide libraries to identify epitopes that activate clonotypic CD4+ T cells and induce T cell responses to native peptide ligands. J. Immunol. 163, 6424 –6434[Abstract/Free Full Text]

  166. Sette, A., and Fikes, J. (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15, 461 –470[CrossRef][Medline]

  167. Purcell, A. W., Zeng, W., Mifsud, N. A., Ely, L. K., Macdonald, W. A., and Jackson, D. C. (2003) Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J. Pept. Sci. 9, 255 –281[CrossRef][Medline]

  168. Stevens, J., Jones, R. C., Bordoli, R. S., Trowsdale, J., Gaskell, S. J., Butcher, G. W. and Joly, E. (2000) Peptide specificity of RT1-A1c, an inhibitory rat major histocompatibility complex class I natural killer cell ligand. J. Biol. Chem. 275, 29217 –29224[Abstract/Free Full Text]

  169. Banks, R. E., Dunn, M. J., Forbes, M. A., Stanley, A., Pappin, D., Naven, T., Gough, M., Harnden, P., and Selby, P. J. (1999) The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis—Preliminary findings. Electrophoresis 20, 689 –700[CrossRef][Medline]

  170. Craven, R. A., Totty, N., Harnden, P., Selby, P. J., and Banks, R. E. (2002) Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: Evaluation of tissue preparation and sample limitations. Am. J. Pathol. 160, 815 –822[Abstract/Free Full Text]

  171. Craven, R. A., and Banks, R. E. (2001) Laser capture microdissection and proteomics: Possibilities and limitation. Proteomics 1, 1200 –1204[CrossRef][Medline]

  172. Suarez-Quian, C. A., Goldstein, S. R., Pohida, T., Smith, P. D., Peterson, J. I., Wellner, E., Ghany, M., and Bonner, R. F. (1999) Laser capture microdissection of single cells from complex tissues. BioTechniques 26, 328 –335[Medline]

  173. Craven, R. A., and Banks, R. E. (2002) Use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis. Methods Enzymol. 356, 33 –49[Medline]

  174. Mouledous, L., Hunt, S., Harcourt, R., Harry, J. L., Williams, K. L., and Gutstein, H. B. (2003) Proteomic analysis of immunostained, laser-capture microdissected brain samples. Electrophoresis 24, 296 –302[CrossRef][Medline]

  175. Ornstein, D. K., Gillespie, J. W., Paweletz, C. P., Duray, P. H., Herring, J., Vocke, C. D., Topalian, S. L., Bostwick, D. G., Linehan, W. M., Petricoin, E. F., 3rd, and Emmert-Buck, M. R. (2000) Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21, 2235 –2242[CrossRef][Medline]

  176. Emmert-Buck, M. R., Bonner, R. F., Smith, P. D., Chuaqui, R. F., Zhuang, Z., Goldstein, S. R., Weiss, R. A., and Liotta, L. A. (1996) Laser capture microdissection. Science 274, 998 –1001[Abstract/Free Full Text]

  177. Bichsel, V. E., Liotta, L. A., and Petricoin, E. F., 3rd (2001) Cancer proteomics: From biomarker discovery to signal pathway profiling Cancer J. 7, 69 –78[Medline]

  178. Wulfkuhle, J. D., McLean, K. C., Paweletz, C. P., Sgroi, D. C., Trock, B. J., Steeg, P. S., and Petricoin, E. F., 3rd (2001) New approaches to proteomic analysis of breast cancer. Proteomics 1, 1205 –1215[CrossRef][Medline]

  179. Paweletz, C. P., Liotta, L. A., and Petricoin, E. F., 3rd (2001) New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 57, 160 –163[CrossRef][Medline]

  180. Simone, N. L., Paweletz, C. P., Charboneau, L., Petricoin, E. F., 3rd, and Liotta, L. A. (2000) Laser capture microdissection: beyond functional genomics to proteomics. Mol. Diagn. 5, 301 –307[CrossRef][Medline]

  181. Bhattacharya, S. H., Gal, A. A., and Murray, K. K. (2003) Laser capture microdissection MALDI for direct analysis of archival tissue. J. Proteome Res. 2, 95 –98[CrossRef][Medline]

  182. Wu, S. L., Hancock, W. S., Goodrich, G. G., and Kunitake, S. T. (2003) An approach to the proteomic analysis of a breast cancer cell line (SKBR-3). Proteomics 3, 1037 –1046[CrossRef][Medline]

  183. Ahram, M., Flaig, M. J., Gillespie, J. W., Duray, P. H, Linehan, W. M., Ornstein, D. K., Niu, S., Zhao, Y., Petricoin, E. F., 3rd, and Emmert-Buck, M. R. (2003) Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 3, 413 –421[CrossRef][Medline]

  184. Zhou, G., Li, H., DeCamp, D., Chen, S., Shu, H., Gong, Y., Flaig, M., Gillespie, J. W., Hu, N., Taylor, P. R., Emmert-Buck, M. R., Liotta, L. A., Petricoin, E. F., 3rd, and Zhao, Y. (2002) 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics 1, 117 –124[Abstract/Free Full Text]

  185. Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., and Petricoin, E. F., 3rd (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76 –84[CrossRef][Medline]

  186. Adam, B. L., Vlahou, A., Semmes, O. J., and Wright, G. L., Jr. (2001) Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1, 1264 –1270[CrossRef][Medline]

  187. Macdonald, W., Williams, D. S., Clements, C. S., Gorman, J. J., Kjer-Nielsen, L., Brooks, A. G., McCluskey, J., Rossjohn, J., and Purcell, A. W. (2002) Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. FEBS Lett.27 –32

  188. Hughes, E. A., and Cresswell, P. (1998) The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr. Biol. 8, 709 –712[Medline]

  189. Lindquist, J. A., Jensen, O. N., Mann, M., and Hammerling, G. J. (1998) ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J. 17, 2186 –2195[Abstract/Free Full Text]

  190. Dick, T. P., and Cresswell, P. (2002) Thiol oxidation and reduction in major histocompatibility complex class I-restricted antigen processing and presentation. Methods Enzymol. 348, 49 –54[Medline]

  191. Dick, T. P., Bangia, N., Peaper, D. R., and Cresswell, P. (2002) Disulfide bond isomerization and the assembly of MHC class I-peptide complexes. Immunity 16, 87 –98[Medline]

  192. Farmery, M. R., Allen, S., Allen, A. J., and Bulleid, N. J. (2000) The role of ERp57 in disulfide bond formation during the assembly of major histocompatibility complex class I in a synchronized semipermeabilized cell translation system. J. Biol. Chem. 275, 14933 –14938[Abstract/Free Full Text]

  193. Grandea, A. G., Lehner, P. J., Cresswell, P., and Spies, T. (1997) Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. Immunogenetics 46, 477 –483[CrossRef][Medline]

  194. Sadasivan, B., Lehner, P. J., Ortmann, B., Spies, T., and Cresswell, P. (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5, 103 –114[Medline]

  195. Brocke, P., Garbi, N., Momburg, F., and Hammerling, G. J. (2002) HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr. Opin. Immunol. 14, 22 –29[CrossRef][Medline]

  196. Fremont, D. H., Monnaie, D., Nelson, C. A., Hendrickson, W. A., and Unanue, E. R. (1998) Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. Immunity 8, 305 –317[Medline]

  197. Gorman, J. J., Ferguson, B. L., Speelman, D., and Mills, J. (1997) Determination of the disulfide bond arrangement of human respiratory syncytial virus attachment (G) protein by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Protein Sci. 6, 1308 –1315[Abstract/Free Full Text]

  198. Lopaticki, S., Morrow, C. J., and Gorman, J. J. (1998) Characterization of pathotype-specific epitopes of newcastle disease virus fusion glycoproteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and post-source decay sequencing. J. Mass Spectrom. 33, 950 –960[CrossRef][Medline]